In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-β-lactamase-producing Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Fujimura, Shigeru ^a   Takane, Hidenari ^a   Nakano, Yoshihisa ^a   Watanabe, Akira ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Antipseudomonal agents; Arbekacin; Chequerboard; Pulmonary infections

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; HABEKACIN; IMIPENEM; MEROPENEM; PAZUFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; PENICILLANIC ACID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DRUG POTENTIATION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 73949121008     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp333     Document Type: Letter

References (7)

1. Ciofu O. Pseudomonas aeruginosa chromosomal β-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. APMIS Suppl 2003; 116: 1-47.
2. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
4. Bajaksouzian S, Visalli MA, Jacobs MR et al. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against Acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother 1997; 41: 1073-6.
5. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
6. Elaichouni A, Verschraegen V, Claeys G et al. Pseudomonas aeruginosa serotype O12 outbreak studied by arbitrary primer PCR. J Clin Microbiol 1994; 32: 666-71.
7. Fujimura S, Gomi K, Takane H et al. Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007. Jpn J Chemother 2009; 57: 91-6. (Japanese).